LOW-VOLUME · HOSP-MID
brodalumab Side Effects
brodalumab (also sold as Siliq) is a LOW-VOLUME FAERS extract #462 of 524 by FAERS report count. Still opens on HOSP-MID: 28.3% mention hospitalization (535 reports).
Data updated 2026-05-15
- 1,890
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
brodalumab: 28.3% mention hospitalization (535 reports). Death stamp DEATH-HEAVY; volume band LOW-VOLUME #462 of 524 by FAERS report count.
Thinner FAERS extract for brodalumab (Siliq) (1,890 reports #462 of 524 by FAERS report count). 28.3% mention hospitalization (535 reports). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2013–2025). Stamps SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
PSORIASIS leads 471 of 1,890 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (646 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (133 reports, 7.0%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 72 |
| PSORIASIS | 11 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 8 |
| BLOOD PRESSURE INCREASED | 7 |
| PNEUMONIA | 7 |
| FALL | 6 |
| ASTHENIA | 5 |
| COUGH | 5 |
| COVID-19 | 5 |
| DISEASE RECURRENCE | 5 |
| FATIGUE | 5 |
| HEADACHE | 5 |
| HOSPITALISATION | 5 |
| ILLNESS | 5 |
| MALAISE | 5 |
| NEOPLASM MALIGNANT | 5 |
| PRURITUS | 5 |
| RENAL FAILURE | 5 |
Reactions in Hospitalization Reports
Hospitalization mid-share (535, 28.3%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| PSORIASIS | 147 |
| HOSPITALISATION | 57 |
| ARTHRALGIA | 45 |
| THERAPY INTERRUPTED | 43 |
| FALL | 41 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 37 |
| COVID-19 | 33 |
| FATIGUE | 31 |
| CONDITION AGGRAVATED | 30 |
| DISEASE RECURRENCE | 30 |
| HEADACHE | 29 |
| PNEUMONIA | 27 |
| PRURITUS | 27 |
| PAIN IN EXTREMITY | 26 |
| PATIENT DISSATISFACTION WITH TREATMENT | 25 |
| DIARRHOEA | 24 |
How to read brodalumab FAERS figures (SIGNAL · DEATH-HEAVY · HOSP-MID)
FAERS holds 1,890 voluntary reports linked to brodalumab (Siliq), 2013-2025. Death is listed on 133 (7.0%). Hospitalization appears on 535 (28.3%). Top co-reported indication: Psoriasis.
Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.
Read with brodalumab
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 1,858 FAERS cases (Δ 32 lighter vs brodalumab); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 1,831 FAERS cases (Δ 59 lighter vs brodalumab); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 1,829 FAERS cases (Δ 61 lighter vs brodalumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 1,963 FAERS cases (Δ 73 heavier vs brodalumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 55.1 pp vs brodalumab's DEATH-HEAVY): CASELOAD · HOSP-MID.
brodalumab stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload SIGNAL and the label guide.